论文部分内容阅读
据报道非糖基化的重组人粒-巨噬细胞集落刺激因子(rhGM-CSF)较糖基化的rhGM-CSF加速自体骨髓移植后造血恢复可能具有更高特异的活性,临床小剂量使用可能是有效的。本文对小剂量非糖基化rhGM-CSF治疗骨髓或外周血干细胞移植后
It has been reported that non-glycosylated recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) may have more specific activity than glycosylated rhGM-CSF in accelerating hematopoietic recovery after autologous bone marrow transplantation. Clinical low-dose use may be It is effective. This article treats low-dose non-glycosylated rhGM-CSF after bone marrow or peripheral blood stem cell transplantation